Search

everythinglearnresearchcommunity

for

Search:↓

The ID2 gene can help distinguish between sensitizers and irritants in skin cells.

Certain immune cells in atopic dermatitis skin could be targeted for treatment.

CD44 signaling can help heal wounds without scars.

Super-enhancers control CD25 expression in specific cell types, affecting immune function.

IL-17C is important in inflammatory skin diseases and could be a target for treatment.

Mice genetically modified to produce more CD109 in their skin had less inflammation and better healing with less scarring.

CXCR2 in skin cells promotes tumor growth.

Deleting the CD271 gene in mouse skin cells leads to disorganized skin and increased hair growth, suggesting CD271 is important for skin health.

Blocking CD44 can reduce leukocyte migration in autoimmune skin diseases.

A substance called poly(I:C) increases a protein called carbonic anhydrase II in skin cells, which might help with skin defense and healing.

CD8+ T cells expand significantly in alopecia areata, suggesting new treatment targets.

CD98hc's role in skin health decreases with age.

A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.

CXXC5 can both suppress and promote cancer, making it a complex target for treatment.

The gp130 receptor helps in tissue regeneration and disease progression, and manipulating it could improve healing and prevent disease.

Topical IKKα inhibitors may help prevent CCS tumours.

Calancardin B may help reduce inflammation in immune cells.

Skin tumors with CYLD cutaneous syndrome show more NF-κB activity and less organized collagen.

CD10 helps distinguish between basal cell carcinoma and benign hair follicle tumors.

Tph cells are linked to the severity of systemic lupus erythematosus.

Monoclonal antibody B72.3 selectively reacts with certain dog tissues, mainly in the gastrointestinal and respiratory tracts.

p120-catenin helps control skin inflammation by regulating cadherin levels.

Higher levels of certain DNAs in blood may indicate hair follicle damage in alopecia areata patients.

Small molecules KY19382 and KY19334 may help treat skin cancer by reducing CDK1 levels and blocking harmful cell signals.

CRISPR/Cas9 and prime editing can potentially fix skin disorder genes safely and effectively.

PI3Kδ inhibition may effectively treat cutaneous chronic graft-versus-host disease.

Contact immunotherapy can change immune responses in alopecia areata, suggesting new treatment targets.

CD28 is a promising target for treating alopecia areata with belatacept.